Advanced Accelerator Applications
As of the edition of 20 October 2026, Advanced Accelerator Applications runs 4 drugs, 3 of them marketed; it is on route A at 0 targets and on route B at 5 targets.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Family history
The records place 2 company names in this family.
Drugs by status
| Status | Count |
|---|---|
| Marketed | 3 |
| Stopped | 1 |
| Total | 4 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Lutetium oxodotreotide | Ends 2031 (exclusivity) | 10 |
| Gallium oxodotreotide | none listed | 0 |
| Rubidium | none listed | 0 |
A route B row is one company at one target.
Where it needs a new molecule
Route A at 0 targets, route B at 5 targets.
All 5 rows on route A or B
In the product5 company-target rows on route A or B; 2 are not shown here, and no score is.
See all 5 targets where Advanced Accelerator Applications needs a new molecule, with the facts behind eachRequest access. Nothing is shown until you do.
Where its trials are
- Cancer: 3 trials led
- Heart and blood vessels: 1 trials led
- Pregnancy and women's health: 1 trials led